Vistagen Faces Class Action Lawsuit; Investors Urged to Act
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2d ago
0mins
Source: Globenewswire
- Class Action Filed: Bragar Eagel & Squire, P.C. has initiated a class action lawsuit against Vistagen on behalf of investors who purchased shares between April 1, 2024, and December 16, 2025, with a deadline of March 16, 2026, to apply as lead plaintiff.
- False Statements Allegation: The lawsuit alleges that Vistagen made misleading positive statements regarding its PALISADE-3 trial while concealing adverse facts about the treatment for social anxiety disorder, resulting in significant investor losses.
- Stock Price Plunge: Following the announcement on December 17, 2025, that the trial did not meet its primary endpoint, Vistagen's stock price plummeted from $4.36 to $0.86, representing an over 80% decline, which severely impacted investor confidence.
- Legal Consultation Opportunity: Affected investors are encouraged to contact Bragar Eagel & Squire for legal advice regarding their rights and potential claims, with no cost or obligation for the consultation.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like VTGN with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on VTGN
Wall Street analysts forecast VTGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTGN is 0.97 USD with a low forecast of 0.90 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
0 Buy
5 Hold
0 Sell
Hold
Current: 0.541
Low
0.90
Averages
0.97
High
1.00
Current: 0.541
Low
0.90
Averages
0.97
High
1.00
About VTGN
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Its neuroscience product candidates include Fasedienol, Itruvone, PH15, PH80, and PH284. Fasedienol, its lead clinical-stage product candidate, is a synthetic neuroactive intranasal pherine in an ongoing U.S. registration-directed Phase III clinical development program for the acute treatment of anxiety in adults with SAD. Its neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vistagen Therapeutics Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Vistagen Therapeutics (NASDAQ: VTGN) common stock between April 1, 2024, and December 16, 2025, to apply as lead plaintiffs by March 16, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that defendants provided misleading information regarding the development and commercialization of fasedienol, claiming high success rates for clinical trials while concealing adverse facts related to the PALISADE-3 trial, resulting in investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its strong track record and expertise in the field.
- Investor Guidance: Investors are advised to select qualified counsel with proven success in securities litigation, avoiding firms that merely act as intermediaries, to ensure effective legal representation in the class action process.
Continue Reading
Vistagen Faces Class Action Lawsuit; Investors Urged to Act
- Class Action Filed: Bragar Eagel & Squire, P.C. has initiated a class action lawsuit against Vistagen on behalf of investors who purchased shares between April 1, 2024, and December 16, 2025, with a deadline of March 16, 2026, to apply as lead plaintiff.
- False Statements Allegation: The lawsuit alleges that Vistagen made misleading positive statements regarding its PALISADE-3 trial while concealing adverse facts about the treatment for social anxiety disorder, resulting in significant investor losses.
- Stock Price Plunge: Following the announcement on December 17, 2025, that the trial did not meet its primary endpoint, Vistagen's stock price plummeted from $4.36 to $0.86, representing an over 80% decline, which severely impacted investor confidence.
- Legal Consultation Opportunity: Affected investors are encouraged to contact Bragar Eagel & Squire for legal advice regarding their rights and potential claims, with no cost or obligation for the consultation.
Continue Reading